The conference will consist of a variety of plenary and parallel sessions, as well as breakout discussion sessions, workshops, a poster session and the Annual General Meeting.

Sessions will include early phase innovative trial design, industry best practice - 10 years on, statistical issues in safety drug labelling, model based dose finding designs, an update from Transcelerate and much more, with speakers from industry, academia and regulatory agencies.